



ACCUSTEM

Building Better Oncology Tools

Investor Presentation

Q3 2025



ACCUSTEM

DISCLAIMER

This presentation contains forward-looking statements that involve risks and uncertainties. You should not place undue reliance on these forward-looking statements. All statements other than statements of historical facts contained in this presentation are forward-looking statements. The forward-looking statements in this presentation are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. In some cases, you can identify these forward-looking statements by terms such as “anticipate,” “believe,” “continue,” “could,” “depends,” “estimate,” “expects,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms or other similar expressions, although not all forward-looking statements contain those words. We have based these forward-looking statements on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, strategy, short-term and long-term business operations and objectives and financial needs.

These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward- looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward- looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations.

These statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from those anticipated by the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by law, we are under no duty to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this presentation. These forward-looking statements speak only as of the date of this presentation, and we assume no obligation to update or revise these forward-looking statements for any reason.

COMPANY OVERVIEW



Our mission at AccuStem (OTCQB: ACUT) is to provide proprietary diagnostic tools that address unanswered clinical questions to improve outcomes for patients and return shareholder value

Our primary product candidate, MSC, evaluates 24 miRNAs to stratify lung nodules according to their risk of malignancy

Our lead “stemness” product, StemPrintER, interrogates the expression of 20 genes to predict likelihood of breast cancer recurrence and benefit of various treatment interventions

AccuStem’s capital efficient business model and low debt burden will maximize investor return on a \$6.3B market opportunity¹

1. Data on file

ACCUSTEM AT A GLANCE

LUNG CANCER PROGRAM	BREAST CANCER/STEMNESS PROGRAM	EFFICIENT CORPORATE EXECUTION
<ul style="list-style-type: none">• In-licensed MSC assay from Istituto Nazionale dei Tumori (INT)• EU patent approved and US and China patents pending• MSC has level one validation data from multiple prospective study cohorts with publications in top tier journals• \$5.5B market opportunity with margins >90%• Commodity testing will be offered along with MSC to generate additional revenue	<ul style="list-style-type: none">• In-licensed StemPrintER assay from Istituto Europeo di Oncologia (IEO)• US and EU patents approved• StemPrintER has been validated in prospective study cohorts and is published in top tier journals• Established collaborations with leading US and EU institutions• \$800M market opportunity in breast cancer with >80% margins• Planning to research stemness across different tumor types	<ul style="list-style-type: none">• Proven leadership team with nearly 60 combined years of experience in the oncology diagnostics sector• Opening research lab to focus on breast and stemness programs• Planning to expand product offering to additional tumor types as resources permit• Evaluating collaboration strategies with industry partners• Forming SAB to support effective product development

ACCUSTEM PRODUCT PIPELINE

AccuStem's mission is to provide proprietary diagnostic tools that address unanswered clinical questions to improve outcomes for patients and return shareholder value

Our capital efficient business model, low debt burden and broad IP protection will maximize investor return

Our initial product candidates, the MSC and StemPrintER tests, represent a \$6.3B market opportunity with attractive margins >80% that improve with scale

ASSET	TARGET MARKET	IP PROTECTION	ANALYTICAL VALIDATION	CLINICAL VALIDATION	LEVEL 1 DATA	US LAB TECH TRANSFER	CLINICAL UTILITY/ HEALTH ECON	CMS COVERAGE
MSC	Lung Cancer	✓	✓	✓	✓	#		
StemPrintER	Breast Cancer	✓	*	*	*	#		

*StemPrintER has analytical validation, clinical validation and Level 1 data for prognosis, not prediction of surgical benefit; #US lab tech transfer has been initiated for MSC and StemPrintER

ACCUSTEM LUNG PROGRAM

LUNG NODULES

- More than 15M patients eligible for LDCT screening (<5% screened today)
- ~1.6M nodules identified annually in the US (>90% are benign)
- LDCT alone provides indeterminate results 80% of the time, leading to unnecessary procedures and increased patient anxiety

MSC TEST

- 24 miRNAs evaluated
- Indicates risk of cancer with NPV >99%
- Enables patients to confidently avoid unnecessary tests and invasive procedures, reducing patient anxiety



LUNG CANCER

- >236K new cancers diagnosed annually in the US
- Five-year survival is ~22%
- ACUT will support treatment planning along the continuum of care

STEMPRINTER (~56K PATIENTS)

- 20 gene test
- Identifies risk of recurrence for stage IA-IIA patients

NGS TESTING (~180K PATIENTS)

- Focused multi-gene panel
- Stage II+ patients
- Informs appropriate systemic therapy

CHALLENGES WITH LUNG CANCER DIAGNOSIS



80%

of LDCT results are indeterminate¹



62%

of patients receiving biopsy as the sole diagnostic procedure were benign²



17%


of patients sent to CT surveillance have malignant nodules³

Current lung cancer risk assessment has led to over- and under-treatment of patients

1. ACCP Guidelines. CHEST, 2013; 2. Silvestri, GA, et al. CHEST. 2018; 3. PANOPTIC data on file


VALIDATION OF MSC IN LUNG CANCER SCREENING

MSC Stratification of Lung Nodules¹



MSC significantly improves the accuracy of LDCT screening for patients at risk of developing lung cancer

MSC Identification of Lung Cancer in CT+ Patients²




MSC+ patients are more than 4 times as likely to have lung cancer as MSC- patients

Combining LDCT and MSC results in a five-fold reduction in false positive rates versus LDCT alone³

1. Pastorino, et al. Annal Oncol. 2022; 2. Boeri, et al. Lancet. 2024; 3. Sozzi, et al. J Clin Oncol. 2014

MSC INTEGRATION INTO LUNG CANCER DIAGNOSTIC WORKUP PROCESS



ACCP Guidelines: Evaluation of Individuals with Pulmonary Nodules- CHEST May 2013

COMPETITIVE LANDSCAPE FOR THE MSC TEST

	AccuStem	Biodesix
Product	MSC Test	Nodify
US Serviceable Market	1,570,000	1,570,000
Reimbursement (CMS)	Est. \$3520	\$3520
Est. 2025 Revenue	N/A	\$80-85M ¹
Lung Nodule Screening	Yes	Yes
Systemic Therapy Benefit (NGS)	Yes	Yes

1. Entire lung cancer diagnostics portfolio, 2025 full guidance

ACCUSTEM BREAST CANCER AND STEMNESS PROGRAM

2M+ new breast cancer diagnoses annually


- No genomic tests to inform surgical approach, benefit of radiation

StemPrintER is a novel 20-gene test designed to measure the "stemness" of tumors

- By evaluating the underlying "stem" biology of tumors, we believe our test will address unanswered clinical questions

StemPrintER is highly prognostic in patients with ER+/HER2- breast cancer

- High Risk patients are up to 4x more likely to experience a distant recurrence compared to Low Risk patients^{1,2}





"Understanding the prognosis of a patient's cancer is critical to effective treatment planning and patient counseling."

-Peter Beitsch, MD

1. Pece, et al. Ebiomedicine. 2019; 2. Pece, et al. Eur J Cancer. 2022

VALIDATION OF STEMPRINTER IN BREAST CANCER



1. Pece, et al. Ebiomedicine. 2019; 2. Pece, et al. Eur J Cancer. 2022

CLINICAL DECISION MAKING IN BREAST CANCER

BIOPSY

Clinical Questions

What is the subtype of cancer?
Is patient a candidate for NAC?
How aggressive is the cancer?

BREAST CANCER GENOMICS

SURGERY

Mastectomy vs. lumpectomy?
Sentinel node vs. full axillary dissection?
Radiation treatment?


THERAPY

Adjuvant Chemotherapy?
Hormone Therapy?



OUR APPROACH TO BREAST CANCER

BREAST CANCER CARE CONTINUUM



“For treatment planning prior to chemotherapy selection, **we do not currently possess tools to determine the most appropriate interventions**, specifically the ideal approach to surgery or radiation”

BREAST CANCER GENOMICS INDUSTRY

	AccuStem	Exact Sciences	Agendia	Hologic	Myriad/Eurobio Scientific	Veracyte
Product	StemPrintER	OncotypeDX	MammaPrint	Breast Cancer Index	EndoPredict	Prosigna
Global Serviceable Market	798,000	562,000	562,000	562,000	562,000	562,000
Reimbursement (CMS)	N/A	\$3873	\$3873	\$3873	\$3873	\$3873
Est. 2025 Revenue	N/A	\$630M	\$75M	\$100M	~\$16M	~\$16M
Risk of Recurrence	Yes	Yes	Yes	Yes	Yes	Yes
Adjuvant Chemo	Yes	Yes	Yes	Yes	Yes	Yes
Surgical/Radiation Planning	Yes	No	No	No	No	No

OUR LEADERSHIP TEAM AND APPROACH: A PROVEN TRACK RECORD

WENDY BLOSSER, CEO

- ✓ 25 years of success building organizations in Oncology and Women's Health
- ✓ Led Oncology Sales at Genzyme Genetics prior to \$925M acquisition by Integrated Oncology (ticker: LH)
- ✓ Cytac leadership prior to \$6.2B Hologic acquisition

JEFF FENSTERER, CSO

- ✓ 20-year track record in diagnostic leadership in a variety of functional roles
- ✓ Extensive experience developing and validating esoteric tests
- ✓ Led extensive product launch/relaunch efforts at Biodesix, Agendia and Precision Therapeutics (Helomics)

JOE FLANAGAN, CBO

- ✓ 18 years of strategic expertise with successful product launches at early-stage diagnostic start ups
- ✓ Drove revenue growth at Biodesix, Agendia, Ambry and Helomics by enhancing sales team clinical agility and logistical processes

KEEREN SHAH, CFO

- ✓ 20 years of experience in controllership, financial planning and analysis and IPO offerings
- ✓ Held variety of finance roles at Visa, Arthur Andersen, BBC Worldwide, Tiziana Life Sciences and Okyo Pharma



INVESTMENT AND COMPANY HIGHLIGHTS

- ✓ Management team with wide-ranging leadership experience across various functional areas, deep relationships with luminary US institutions and a track record of successful launch/relaunch strategies
- ✓ MSC's level 1 data, published in several top tier journals, positions it well to be the market leader in the \$5.5B lung cancer screening space
- ✓ Our proprietary "stemness" platform is validated for predicting breast cancer risk of recurrence (StemPrintER) and further demonstration of its novel utility is expected to enable an \$800M expansion of the genomics market
- ✓ AccuStem has a compelling product portfolio with strong IP protection and margins >80% that will scale with volume



THANK YOU FOR YOUR
CONSIDERATION



Info@Accustem.com | Accustem.com